TargetSp15+-+Enoyl-ACP+reductase+FabV+(Yersinia+Pestis)


 * Target (protein/gene name):** FabV Enoyl-ACP Reductase
 * NCBI Gene** # **or RefSeq#:** 372467227


 * Protein ID (NP or XP #) or Wolbachia#:** ZP_04462052.1

The Bubonic Plague is very well known to many for its disastrous effects on medieval Europe. Yersenia pestis, a bacterium, was identified in 1894 to be the cause of this horrible disease. The plague is still alive today, seen mostly in the Americas, Asia, and Africa. Treatment for the disease is very effective when diagnosed early on. However, drug-resistant strains were identified in 1995, and from then on, there have been more drug-resistant strains emerging. Along with this, many fear it can be used as a biological weapon. So, there has been pressure to find new drug targets rather quickly. []
 * Organism (including strain):** Yersenia pestis
 * Etiologic Risk Group (see link below):** Appendix B-III-A. Risk Group 3 (RG3) - Bacterial Agents Including Rickettsia
 * Disease Information (sort of like the Intro to your Mini Research Write up):**

[] Isoniazid, one of the front-line drugs against tuberculosis, and triclosan, a broad-spectrum antiseptic, both inhibit the last and rate limiting step of the FAS-II pathway, where enoyl-ACP reductase is necssary. FabV, an isoform of enoyl-ACP reductase, is found in Y. pestis. [] http://www.brenda-enzymes.org/enzyme.php?ecno=1.3.1.9&Suchword=&organism[]=Yersinia+pestis&show_tm=0
 * Link to Gene Database page (NCBI, EuPath databases -e.g. TryTryp, PlasmoDB, etc - or PATRIC, etc.)**
 * Essentiality of this protein:** Catalyzes last step of the bacterial fatty acid biosynthesis (FAS-II) pathway
 * Is it a monomer or multimer as biological unit?** Monomer
 * Complex of proteins?:**
 * Druggable Target (list number or cite evidence from a paper/database showing druggable in another organism):**
 * EC#:** 1.3.1.9
 * Link to BRENDA EC# page:**

[] NAD/NADH 10 mL Catalog # G9071 $467.00 NAD/NADH 50 mL Catalog # G9072 $1870.00
 * -- Show screenshot of BRENDA enzyme mechanism schematic**
 * Enzyme Assay information (spectrophotometric, coupled assay ?, reagents):**
 * -- link to Sigma (or other company) page for assay (see Sigma links below)**
 * -- -or link (or citation) to paper that contains assay information**
 * -- links to assay reagents (substrates) pages.**
 * --- List cost and quantity of substrate reagents, supplier, and catalog #**
 * Structure (PDB or Homology model)**
 * -- PDB # or closest PDB entry if using homology model:** 3ZU5

1-(2-chlorobenzyl)-4-hexylpyridin-2(1H)-one 1-(3-amino-2-methylbenzyl)-4-hexylpyridin-2(1H)-one triclosan
 * Current Inhibitors:**


 * Expression Information (has it been expressed in bacterial cells):** Expressed in //B. pseudomallei//
 * Purification Method:**
 * Image of protein (PyMol with features delineated and shown separately):**
 * Amino Acid Sequence (paste as text only - not as screenshot or as 'code'):**


 * 1 ||  || GSHMLEMIIK PRVRGFICVT AHPTGCEANV KKQIDYVTTE GPIANGPKRV ||
 * 51 ||  || LVIGASTGYG LAARITAAFG CGADTLGVFF ERPGEEGKPG TSGWYNSAAF ||
 * 101 ||  || HKFAAQKGLY AKSINGDAFS DEIKQLTIDA IKQDLGQVDQ VIYSLASPRR ||
 * 151 ||  || THPKTGEVFN SALKPIGNAV NLRGLDTDKE VIKESVLQPA TQSEIDSTVA ||
 * 201 ||  || VMGGEDWQMW IDALLDAGVL AEGAQTTAFT YLGEKITHDI YWNGSIGAAK ||
 * 251 ||  || KDLDQKVLAI RESLAAHGGG DARVSVLKAV VSQASSAIPM MPLYLSLLFK ||
 * 301 ||  || VMKEKGTHEG CIEQVYSLYK DSLCGDSPHM DQEGRLRADY KELDPEVQNQ ||
 * 351 ||  || VQQLWDQVTN DNIYQLTDFV GYKSEFLNLF GFGIDGVDYD ADVNPDVKIP ||
 * 401 ||  || NLIQG ||
 * 151 ||  || THPKTGEVFN SALKPIGNAV NLRGLDTDKE VIKESVLQPA TQSEIDSTVA ||
 * 201 ||  || VMGGEDWQMW IDALLDAGVL AEGAQTTAFT YLGEKITHDI YWNGSIGAAK ||
 * 251 ||  || KDLDQKVLAI RESLAAHGGG DARVSVLKAV VSQASSAIPM MPLYLSLLFK ||
 * 301 ||  || VMKEKGTHEG CIEQVYSLYK DSLCGDSPHM DQEGRLRADY KELDPEVQNQ ||
 * 351 ||  || VQQLWDQVTN DNIYQLTDFV GYKSEFLNLF GFGIDGVDYD ADVNPDVKIP ||
 * 401 ||  || NLIQG ||
 * 251 ||  || KDLDQKVLAI RESLAAHGGG DARVSVLKAV VSQASSAIPM MPLYLSLLFK ||
 * 301 ||  || VMKEKGTHEG CIEQVYSLYK DSLCGDSPHM DQEGRLRADY KELDPEVQNQ ||
 * 351 ||  || VQQLWDQVTN DNIYQLTDFV GYKSEFLNLF GFGIDGVDYD ADVNPDVKIP ||
 * 401 ||  || NLIQG ||
 * 351 ||  || VQQLWDQVTN DNIYQLTDFV GYKSEFLNLF GFGIDGVDYD ADVNPDVKIP ||
 * 401 ||  || NLIQG ||
 * 351 ||  || VQQLWDQVTN DNIYQLTDFV GYKSEFLNLF GFGIDGVDYD ADVNPDVKIP ||
 * 401 ||  || NLIQG ||
 * 401 ||  || NLIQG ||
 * 401 ||  || NLIQG ||

ATGATTATCAAGCCGCGTGTACGTGGTTTTATCTGTGTTACTGCGCATCCAACGGGTTGCGAGGCTAACGTGAA AAAACAGATCGACTACGTTACCACCGAAGGTCCGATTGCGAACGGTCCGAAACGTGTTCTGGTTATTGGTGCG TCTACCGGTTACGGTCTGGCAGCCCGTATCACGGCGGCTTTTGGTTGCGGCGCAGATACCCTGGGCGTTTTCTT CGAACGTCCTGGCGAAGAAGGCAAACCGGGTACGTCTGGTTGGTACAATTCTGCGGCGTTCCACAAATTCGCT GCGCAAAAAGGTCTGTACGCGAAATCTATCAACGGTGATGCGTTCTCTGACGAAATTAAGCAGCTCACCATTGA CGCGATCAAACAGGACCTCGGTCAGGTTGACCAAGTTATTTACTCTCTCGCGTCTCCACGTCGTACCCACCCGA AGACCGGTGAAGTTTTCAACTCTGCGCTGAAACCTATTGGTAATGCTGTAAATCTGCGTGGCCTGGACACCGAC AAAGAAGTTATCAAAGAATCTGTCCTGCAGCCGGCGACCCAGTCTGAAATCGACTCTACCGTTGCGGTCATGGG CGGTGAGGATTGGCAAATGTGGATCGATGCCCTCCTGGACGCGGGTGTTCTCGCGGAAGGTGCCCAAACCACC GCGTTCACCTACCTGGGTGAGAAAATCACGCACGATATCTATTGGAACGGTTCTATCGGTGCGGCGAAAAAAGA CCTGGACCAGAAAGTTCTGGCGATCCGTGAATCTCTGGCGGCTCACGGTGGCGGCGATGCTCGTGTTTCTGTTC TGAAAGCGGTTGTTACCCAGGCGTCTTCTGCGATCCCTATGATGCCGCTCTACCTGTCTCTGCTGTTCAAAGTTAT GAAAGAGAAAGGTACGCATGAAGGTTGCATCGAGCAGGTCTACTCCCTCTACAAAGATTCTCTGTGCGGTGATT CTCCGCACATGGACCAAGAAGGTCGTCTCCGTGCGGACTACAAGGAGCTCGACCCTGAAGTCCAGAATCAGG TTCAGCAGCTGTGGGACCAGGTGACCAACGACAACATCTACCAACTGACGGATTTCGTGGGTTACAAATCTGAA TTCCTCAACCTCTTCGGTTTCGGTATCGACGGTGTTGACTACGACGCGGATGTTAACCCGGACGTCAAAATCCCG AATCTGATCCAGGGTTAA __ATGATTATCAAGCCGCGTGT__ACGTGGTTTTATCTGTGTTACTGCGCATCCAACGGGTTGCGAGGCTAACGTGAAAA AACAGATCGACTACGTTACCACCGAAGGTCCGATTGCGAACGGTCCGAAACGTGTTCTGGTTATTGGTGCGTCTA CCGGTTACGGTCTGGCAGCCCGTATCACGGCGGCTTTTGGTTGCGGCGCAGATACCCTGGGCGTTTTCTTCGAAC GTCCTGGCGAAGAAGGCAAACCGGGTACGTCTGGTTGGTACAATTCTGCGGCGTTCCACAAATTCGCTGCGCAA AAAGGTCTGTACGCGAAATCTATCAACGGTGATGCGTTCTCTGACGAAATTAAGCAGCTCACCATTGACGCGATCA AACAGGACCTCGGTCAGGTTGACCAAGTTATTTACTCTCTCGCGTCTCCACGTCGTACCCACCCGAAGACCGGTG AAGTTTTCAACTCTGCGCTGAAACCTATTGGTAATGCTGTAAATCTGCGTGGCCTGGACACCGACAAAGAAGTTAT CAAAGAATCTGTCCTGCAGCCGGCGACCCAGTCTGAAATCGACTCTACCGTTGCGGTCATGGGCGGTGAGGATTG GCAAATGTGGATCGATGCCCTCCTGGACGCGGGTGTTCTCGCGGAAGGTGCCCAAACCACCGCGTTCACCTACCT GGGTGAGAAAATCACGCACGATATCTATTGGAACGGTTCTATCGGTGCGGCGAAAAAAGACCTGGACCAGAAAGT TCTGGCGATCCGTGAATCTCTGGCGGCTCACGGTGGCGGCGATGCTCGTGTTTCTGTTCTGAAAGCGGTTGTTACC CAGGCGTCTTCTGCGATCCCTATGATGCCGCTCTACCTGTCTCTGCTGTTCAAAGTTATGAAAGAGAAAGGTACGCA TGAAGGTTGCATCGAGCAGGTCTACTCCCTCTACAAAGATTCTCTGTGCGGTGATTCTCCGCACATGGACCAAGAA GGTCGTCTCCGTGCGGACTACAAGGAGCTCGACCCTGAAGTCCAGAATCAGGTTCAGCAGCTGTGGGACCAGGT GACCAACGACAACATCTACCAACTGACGGATTTCGTGGGTTACAAATCTGAATTCCTCAACCTCTTCGGTTTCGGTAT CGACGGTGTTGACTACGACGCGGATGTTAACCCGGACGTCAAAATCCCG__AATCTGATCCAGGGTTAA__
 * length of your protein in Amino Acids:** 405
 * Molecular Weight of your protein in kiloDaltons using the [|Expasy ProtParam] website:** 43986.8
 * Molar Extinction coefficient of your protein at 280 nm wavelength:** 48610
 * TMpred graph Image (@http://www.ch.embnet.org/software/TMPRED_form.html). Input your amino acid sequence to it.**
 * CDS Gene Sequence (paste as text only):**
 * GC% Content for gene: 52.5%**
 * CDS Gene Sequence (codon optimized) - copy from output of Primer Design Protocol (paste as text only):**
 * GC% Content for gene (codon optimized): 52.5%**


 * Do Not Need this info for Spring (but still copy these lines to your Target page for now)**
 * Primer design results for pNIC-Bsa4 cloning (list seqeunces of all of your ~40 nt long primers):**
 * (link to DNA Works output text file - that should be saved in your Google Docs folder after you did the primer design protocol)**
 * -- Ask a mentor, Dr. B, or a fellow researcher -how to link a GDocs file if you are not sure how to.**


 * Primer design results for 'tail' primers (this is just 2 sequences):**